Survival outcomes in liver transplantation for hepatocellular carcinoma, comparing impact of hepatitis C versus other etiology of cirrhosis

Adel Bozorgzadeh, Mark Orloff, Peter Abt, Georgios Tsoulfas, Durald Younan, Randeep Kashyap, Ashok Jain, Parvez Mantry, Benedict Maliakkal, Alok Khorana, Seymour Schwartz – 30 May 2007 – The incidence of hepatocellular carcinoma (HCC) is on the rise worldwide as the most common primary hepatic malignancy. In the US approximately one half of all HCC is related to Hepatitis C virus (HCV) infection. The relationship between the primary disease and HCC recurrence after liver transplantation is unknown.

Hepatitis B x antigen up‐regulates vascular endothelial growth factor receptor 3 in hepatocarcinogenesis

Zhaorui Lian, Jie Liu, Mengchao Wu, Hong‐Yang Wang, Patrick Arbuthnot, Michael Kew, Mark A. Feitelson – 30 May 2007 – Hepatitis B x antigen (HBxAg) is a trans‐activating protein that contributes to liver cancer, in part, by altering the expression of cellular genes. However, few natural effectors of HBxAg have been identified. Hence, HBxAg positive and negative HepG2 cells were prepared and analyzed by PCR select cDNA subtraction.

Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy

Winnie Yeo, Frankie K. F. Mo, Stephen L. Chan, Nancy W. Y. Leung, Pun Hui, Wai‐Yip Lam, Tony S. K. Mok, Kowk C. Lam, Wing M. Ho, Jane Koh, Julian W. Tang, Anthony T. Chan, Paul K. S. Chan – 30 May 2007 – HCC is a common cause of morbidity and mortality. For patients who are not candidates for curative surgery, systemic chemotherapy is one of the standard treatments. In parts of China and the Far East, over 80% of HCC patients have chronic HBV infection. In this study, we aimed to assess the relationship between pre‐chemotherapy HBV viral load and the survival of HCC patients.

Remarkable heterogeneity displayed by oval cells in rat and mouse models of stem cell–mediated liver regeneration

Peter Jelnes, Eric Santoni‐Rugiu, Morten Rasmussen, Susanne Lunøe Friis, Jens Høiriis Nielsen, Niels Tygstrup, Hanne Cathrine Bisgaard – 30 May 2007 – The experimental protocols used in the investigation of stem cell–mediated liver regeneration in rodents are characterized by activation of the hepatic stem cell compartment in the canals of Hering followed by transit amplification of oval cells and their subsequent differentiation along hepatic lineages.

Rapidly progressive recurrent hepatitis C virus infection starting 9 days after liver transplantation

Neeraj Saraf, M. Isabel Fiel, Graciela DeBoccardo, Sukru Emre, Thomas D. Schiano – 30 May 2007 – Early histological recurrence of hepatitis C after liver transplantation (LT) has a negative impact on patient and graft survival. We report a case of histological recurrence of HCV occurring in the second week after LT. A 75‐year‐old woman with chronic HCV and hepatocellular carcinoma underwent LT with an organ from a 75‐year‐old HCV‐negative deceased donor.

Thrombolysis for early hepatic artery thrombosis: Definitive therapy or diagnostic aid?

James D. Perkins – 30 May 2007 – Hepatic artery thrombosis is an uncommon complication of liver transplantation. However, it is a major indication for re‐transplantation. The use of transcatheter thrombolysis and subsequent surgical revascularization as a graft salvage procedure is discussed. Four of 5 cases (80%) were successful in re‐establishing flow and uncovering underlying arterial anatomic defects. None were treated definitively by endoluminal measures due to an inability to resolve the underlying anatomic defects.

Sirolimus‐induced pneumonitis following liver transplantation

Rebecca J. Roberts, Antonia C. Wells, Esther Unitt, Meryl Griffiths, Angela D. Tasker, Michael E.D. Allison, J. Andrew Bradley, Christopher J.E. Watson – 30 May 2007 – Sirolimus‐induced pneumonitis has emerged as a potentially serious complication in renal transplantation but only single case reports of this condition have been described after liver transplantation (LT), where experience with sirolimus is relatively limited. We report our experience, the largest to date, of sirolimus‐induced pneumonitis following LT.

Subscribe to